Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleToxicology

Elucidation of the Mechanisms through Which the Reactive Metabolite Diclofenac Acyl Glucuronide Can Mediate Toxicity

Renato J. Scialis and José E. Manautou
Journal of Pharmacology and Experimental Therapeutics April 2016, 357 (1) 167-176; DOI: https://doi.org/10.1124/jpet.115.230755
Renato J. Scialis
Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José E. Manautou
Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Visual representation of a mechanistic two-compartmental transporter model. The movement of DCF-AG in the proposed model is described by three vectorial processes: 1) Pdif,in, passive diffusion from the buffer into the cell; 2) Kactive, active transport from the buffer into the cell; and 3) Pdif,out, passive diffusion from the cell into the buffer. Active transport for this model applies for the OATP2B1-mediated uptake of DCF-AG. Using differential equations within Berkeley Madonna software, the mass transfer of DCF-AG into and out of each compartment is modeled over time using in vitro time-course data to derive kinetic parameters such as Km, Pdif, and Vmax. Pdif reflects passive diffusion while Km and Vmax are used to characterize active uptake that adheres to Michaelis-Menten kinetics. Kinetic parameterization was performed for uptake at pH 6.0 and 7.4 to reflect the physiologic conditions of the intestine and liver, respectively.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Concentration-versus-time profiles of DCF-AG uptake by OATP2B1. HEK-WT and HEK-OATP2B1 cells were seeded for 48 hours and incubated with increasing concentrations of DCF-AG at multiple time points in buffer titrated to either pH 6.0 or 7.4 at 37°C. Intracellular concentrations were determined by LC–MS/MS, and the concentrations were modeled in Berkeley Madonna. (A) and (B) show the uptake of DCF-AG by HEK-OATP2B1 cells at pH 6.0 and 7.4, respectively. Fitted lines from a two-compartment model represent the best fit. Data are the individual replicates from a typical study.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Cytotoxicity of DCF and DCF-AG using HEK cells. HEK-OATP2B1 cells were incubated in the absence or presence of increasing concentrations of compound. Incubations were conducted for 3, 6, or 12 hours at 37°C. Cytotoxicity was assessed using calcein AM to determine live cells and ethidium homodimer-1 as an indicator of dead cells. The CAM and EthD-1 responses indicate concentration-dependent cell death by DCF, and the cytotoxicity was more pronounced for DCF-AG. *P < 0.05, **P < 0.01; ***P < 0.001 compound versus its time-matched vehicle incubation. RFU, relative fluorescence units.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Generation of reactive oxygen species by in HEK cells. HEK-OATP2B1 cells were incubated in the absence or presence of increasing concentrations of compound. Incubations were conducted for 1, 2, or 3 hours at 37°C, after which ROS were detected with the use of DCFDA, which becomes oxidized by ROS to a fluorogenic form. Fluorescence was normalized to vehicle controls and expressed as percentage change from vehicle. Each bar represents the mean ± the standard deviation of n = 3 measurements per condition. *P < 0.05, **P < 0.01; ***P < 0.001 compound versus its time-matched vehicle incubation. RFU, relative fluorescence units.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Inhibition of superoxide dismutase as an indication of oxidative stress. Copper/zinc SOD was incubated in the absence or presence of increasing concentrations of DCF (□) or DCF-AG (▪) for 30 minutes at room temperature (∼25°C). Vehicle shows assay performance in the presence of the same level of organic solvent (dimethyl sulfoxide) used in the inhibitor incubations. Each bar reflects the mean ± standard error of the mean from three separate studies (n = 2 replicates per study). **P < 0.01, ***P < 0.001 inhibitor versus its vehicle incubation. #P < 0.05, ###P < 0.001 for DCF versus DCF-AG.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    COX-1 inhibition profiles of DCF, OH-DCF, and DCF-AG. Recombinant COX-1 was incubated in the presence of inhibitors for 2 minutes at 37°C, and the formation of PGE2 from AA was monitored via LC–MS/MS. Data reflect the mean ± standard error of the mean from three separate studies (n = 2 replicates per study). Inhibition data were fit with a three-parameter model to calculate IC50. Dotted lines reflect the 95% confidence intervals of the fit.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    COX-2 inhibition profiles of DCF, OH-DCF, and DCF-AG. Recombinant COX-2 was incubated in the presence of inhibitors for 2 minutes at 37°C, and the formation of PGE2 from arachidonic acid was monitored via LC–MS/MS. Data reflect the mean ± standard error of the mean from three separate studies (n = 2 replicates per study). Inhibition data were fit with a three parameter model to calculate IC50. Dotted lines reflect the 95% confidence intervals of the fit.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Proposed pathways on the disposition and mechanisms of toxicity for DCF-AG. DCF-AG is generated in the liver after DCF (intraperitoneal or by mouth) administration, where it undergoes excretion into bile or blood via ABC transporters. In the intestinal lumen DCF-AG is taken up by OATPs and exerts various effects that lead to intestinal injury. The absence of MRP3 exacerbates GI injury from DCF-AG owing to the loss of a clearance mechanism from enterocytes. Solid arrows indicate vectorial transport via uptake or efflux transporters, or via blood flow. Dotted arrows signify transport by passive processes. Dashed lines demonstrate possible enzymatic reactions such as inhibition of COX, generation of ROS, or cleavage by bacterial β-glucuronidases (β-gluc). The question mark denotes uncertainty regarding the efflux pathways for the indicated metabolites.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Summary of DCF-AG uptake kinetics mediated by OATP2B1

    Each value represents the mean ± standard error of the mean from three studies (n = 2 replicates per study). *P < 0.05 for pH 6.0 versus pH 7.4.

    Media pHVmaxKmUptake CLintPdif
    pmol/min 
per milligramμMμl/min 
per milligramμl/min 
per milligram
    6.027.8 ± 4.1*15.2 ± 0.81.82 ± 0.190.0522 ± 0.0120*
    7.417.6 ± 1.514.3 ± 0.11.23 ± 0.110.0245 ± 0.0030
    • CLint, intrinsic uptake clearance.

    • View popup
    TABLE 2

    Summary of in vitro COX inhibition assays

    IC50 values reflect the mean ± standard error of the mean from three experiments (n = 2 replicates per experiment).

    CompoundCOX-1 IC50COX-2 IC50
    μMμM
    SC-560 (COX-1 selective)0.00166 ± 0.00022N.D.
    DuP-697 (COX-2 selective)N.D.0.00714 ± 0.0007
    DCF0.0206 ± 0.00370.103 ± 0.005
    OH-DCF0.375 ± 0.07521.2 ± 0.3
    DCF-AG0.620 ± 0.1052.91 ± 0.36
    • N.D., not determined.

Additional Files

  • Figures
  • Tables
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Figure 1 - Cytotoxicity caused by DCF-AG in HEK wild-type and OATP2B1-transfected cells.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 357 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 357, Issue 1
1 Apr 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Elucidation of the Mechanisms through Which the Reactive Metabolite Diclofenac Acyl Glucuronide Can Mediate Toxicity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleToxicology

Mechanisms of Toxicity Caused by Diclofenac Acyl Glucuronide

Renato J. Scialis and José E. Manautou
Journal of Pharmacology and Experimental Therapeutics April 1, 2016, 357 (1) 167-176; DOI: https://doi.org/10.1124/jpet.115.230755

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleToxicology

Mechanisms of Toxicity Caused by Diclofenac Acyl Glucuronide

Renato J. Scialis and José E. Manautou
Journal of Pharmacology and Experimental Therapeutics April 1, 2016, 357 (1) 167-176; DOI: https://doi.org/10.1124/jpet.115.230755
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Tolerability profile of a GalNAc3-conjugated ASO in Monkeys
  • Preclinical Safety of Lung Instillation of Thyroid Hormone
  • Nefazodone Inhibits Anaerobic Glycolysis
Show more Toxicology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics